Clinical Trial Search

Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…

Primary: Physician Global Assessment (PGA) of Skin Overall Response — 5; 5; 0; 0 Participants

Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale

Primary: Self-reported Pain Scores Using 100m Visual Analog Scale 0-100 Pain Score. — 6.4; 12.3 mm

Primary: Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) at Week 16 — 50.0; 21.9 percentage of participants — p=0.0129

Primary: Change in Patient-Reported Itch — -0.33 units on a scale

Primary: Change in Severity of Lesions(Degree of Reticular, Erythematous and Ulceration) by Using Piboonniyom REU Severity Score — 2.15; 0.73 Scores on a scale — p=0.004

Primary: Change in Lichen Planopilaris Activity Index (LLPAI) — -42.9; -66.7 percentage of change from baseline — p=0.014

Primary: Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP — 44.0; 58.2; 37.5; 23.1 percentage of participants

Primary: Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP) — -22; 0; -17; 0 percent change

Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale

Primary: Pain — 0; 4; 4.4 units on a scale

Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980

Primary: Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score — 9 Participants

Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants

Primary: Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators — 1.85; 0.65; 0.65; 0.73 score on…

Primary: Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12 — -37.05; -42.76 percent change

Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale

Primary: Serum Leptin Level — 13.23; 4.20 ng/ml

Primary: Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria — 0; 11; 0; 10 Participants

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Change in SkinDEX-29 Score — -16.83; -5.92 score on a scale — p=0.007

Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale

Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108

Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants

Primary: Maximum Tolerated Dose — 8 J/cm2

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: Investigator's Static Global Assessment Scale (ISGA) Scores — 1.46; 2.02; 2.57; 2.60 Score